BR112019003987A2 - formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc - Google Patents

formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc

Info

Publication number
BR112019003987A2
BR112019003987A2 BR112019003987A BR112019003987A BR112019003987A2 BR 112019003987 A2 BR112019003987 A2 BR 112019003987A2 BR 112019003987 A BR112019003987 A BR 112019003987A BR 112019003987 A BR112019003987 A BR 112019003987A BR 112019003987 A2 BR112019003987 A2 BR 112019003987A2
Authority
BR
Brazil
Prior art keywords
solid forms
cenicriviroc mesylate
mesylate solid
production processes
cenicriviroc
Prior art date
Application number
BR112019003987A
Other languages
English (en)
Portuguese (pt)
Inventor
Kay Sharp Emma
Ian Cooper Martin
Phiasivongsa Pasit
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of BR112019003987A2 publication Critical patent/BR112019003987A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019003987A 2016-08-31 2017-08-30 formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc BR112019003987A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
BR112019003987A2 true BR112019003987A2 (pt) 2019-05-28

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003987A BR112019003987A2 (pt) 2016-08-31 2017-08-30 formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc

Country Status (13)

Country Link
US (1) US10301287B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506896A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019526628A (cg-RX-API-DMAC7.html)
KR (1) KR20190057066A (cg-RX-API-DMAC7.html)
CN (1) CN110167550A (cg-RX-API-DMAC7.html)
AU (1) AU2017321594A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003987A2 (cg-RX-API-DMAC7.html)
CA (1) CA3034606A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019002057A (cg-RX-API-DMAC7.html)
RU (1) RU2019109019A (cg-RX-API-DMAC7.html)
SG (1) SG11201901438VA (cg-RX-API-DMAC7.html)
TW (1) TW201823235A (cg-RX-API-DMAC7.html)
WO (1) WO2018045043A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245589A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245534A1 (en) * 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
EP4159730A4 (en) 2020-05-22 2024-05-01 Medshine Discovery Inc. PYRIDINE DERIVATIVE AND APPLICATION THEREOF
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
EP1104416A2 (en) 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2384145A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
EP1728504B1 (en) 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2818308A1 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
CA2941411A1 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
WO2015187663A1 (en) * 2014-06-02 2015-12-10 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
SG11201704837VA (en) 2014-12-23 2017-07-28 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs

Also Published As

Publication number Publication date
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
RU2019109019A3 (cg-RX-API-DMAC7.html) 2021-08-23
WO2018045043A1 (en) 2018-03-08
RU2019109019A (ru) 2020-10-01
US20180057481A1 (en) 2018-03-01
SG11201901438VA (en) 2019-03-28
TW201823235A (zh) 2018-07-01
CN110167550A (zh) 2019-08-23
KR20190057066A (ko) 2019-05-27
AU2017321594A1 (en) 2019-04-18
US10301287B2 (en) 2019-05-28
EP3506896A1 (en) 2019-07-10
MX2019002057A (es) 2019-11-18
EP3506896A4 (en) 2020-08-26
CA3034606A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2018014154A (es) Polinucleotidos moduladores.
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
IL259023A (en) Compositions containing protein loaded exosomes and methods for preparing same and uses thereof
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX388350B (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
MX376083B (es) Formas de dosificacion solidas de palbociclib.
PT3317260T (pt) Composições de acessulfame de potássio e processos de produção das mesmas
BR112016030284A2 (pt) Formulações, seu uso ou produção de detergentes de lavagem de louça e sua produção
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
HUE072609T2 (hu) Fenfluramin-készítmények és elõállítási eljárásaik
MX2019009485A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX387402B (es) Formulaciones eutécticas de clorhidrato de ciclobenzaprina.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
PT3393485T (pt) Composições probióticas e uso das mesmas
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
EA201791716A1 (ru) Фармацевтический состав
MX2017000862A (es) Formulacion de factor viii.

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements